Outcomes, risk factors, and procedural management of acute myocardial infarction caused by stent thrombosis

Abstract

Coronary stent thrombosis (ST) is a rare but severe complication of percutaneous coronary interventions (PCIs) with significant implications for patient outcomes. Despite advancements in antiplatelet medications and drug-eluting stent (DES) technology, ST remains associated with considerable morbidity and mortality. Notably, ST is an adverse event arising from various factors, including patient characteristics, stent-related issues, and procedural complications. In such a context, intravascular imaging (IVI) plays a pivotal role in assessing the underlying mechanisms and guiding treatment decisions. The use of thrombus aspiration and intracoronary antithrombotic therapies have been debated in the context of de novo acute myocardial infarction, but they could have a remarkable role for ST. However, the optimal management of ST requires individualized approaches tailored to patient-specific factors. This review provides a comprehensive analysis of the current understanding of ST, encompassing its incidence, outcomes, and risk factors, focusing on procedural acute management.

Keywords

Stent thrombosis / acute myocardial infarction / percutaneous coronary intervention

References

[1] Gori T,Indolfi C,Adriaenssens T.Predictors of stent thrombosis and their implications for clinical practice.Nat Rev Cardiol2019;16:243-56

[2] Serruys PW,Beatt KJ.Angiographic follow-up after placement of a self-expanding coronary-artery stent.N Engl J Med1991;324:13-7

[3] Colombo A,Nakamura S.Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance.Circulation1995;91:1676-88

[4] Schömig A,Kastrati A.A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents.N Engl J Med1996;334:1084-9

[5] Klein LW,Maehara A.SCAI expert consensus statement on management of in-stent restenosis and stent thrombosis.J Soc Cardiovasc Angiogr Interv2023;2:100971

[6] Farooq V,Zhang Y.Short-term and long-term clinical impact of stent thrombosis and graft occlusion in the SYNTAX trial at 5 years: synergy between percutaneous coronary intervention with taxus and cardiac surgery trial.J Am Coll Cardiol2013;62:2360-9

[7] Secemsky EA,Yeh RW.Comparison of short- and long-term cardiac mortality in early versus late stent thrombosis (from pooled PROTECT trials).Am J Cardiol2015;115:1678-84

[8] Kristensen SL,Thuesen L.Stent thrombosis is the primary cause of ST-segment elevation myocardial infarction following coronary stent implantation: a five year follow-up of the SORT OUT II study.PLoS One2014;9:e113399 PMCID:PMC4237454

[9] Burzotta F,Pristipino C.Angiographic and clinical outcome of invasively managed patients with thrombosed coronary bare metal or drug-eluting stents: the OPTIMIST study.Eur Heart J2008;29:3011-21

[10] Cutlip DE,Mehran R.Clinical end points in coronary stent trials: a case for standardized definitions.Circulation2007;115:2344-51

[11] Cutlip DE,Ho KK.Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials.Circulation2001;103:1967-71

[12] Chau KH,Easterwood RM.Stent thrombosis risk over time on the basis of clinical presentation and platelet reactivity: analysis from ADAPT-DES.JACC Cardiovasc Interv2021;14:417-27

[13] Ariotti S,Costa F.Is bare-metal stent implantation still justifiable in high bleeding risk patients undergoing percutaneous coronary intervention?: A pre-specified analysis from the ZEUS trial.JACC Cardiovasc Interv2016;9:426-36

[14] Varenne O,Sideris G.Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial.Lancet2018;391:41-50

[15] Tolleson TR,Harrington RA.Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials).Am J Cardiol2003;92:330-3

[16] Costa JR Jr,Moreira AC.Incidence and predictors of very late (>or=4 years) major cardiac adverse events in the DESIRE (drug-eluting stents in the real world)-late registry.JACC Cardiovasc Interv2010;3:12-8

[17] Kubo S,Ichinohe T.Comparison of long-term outcome after percutaneous coronary intervention for stent thrombosis between early, late, and very late stent thrombosis.Circ J2014;78:101-9

[18] Navarese EP,Kandzari D.First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients.Open Heart2014;1:e000064 PMCID:PMC4189321

[19] Torii S,Mori H.Acute thrombogenicity of fluoropolymer-coated versus biodegradable and polymer-free stents.EuroIntervention2019;14:1685-93

[20] Claessen BE,Jaffer FA,Piek JJ.Stent thrombosis: a clinical perspective.JACC Cardiovasc Interv2014;7:1081-92

[21] Brodie B,Garg A.Predictors of early, late, and very late stent thrombosis after primary percutaneous coronary intervention with bare-metal and drug-eluting stents for ST-segment elevation myocardial infarction.JACC Cardiovasc Interv2012;5:1043-51

[22] Schochlow K,Blachutzik F.Coronary stent strut fractures: classification, prevalence and clinical associations.J Clin Med2021;10:1765 PMCID:PMC8072680

[23] Natsuaki M,Morimoto T.An aspirin-free versus dual antiplatelet strategy for coronary stenting: STOPDAPT-3 randomized trial.Circulation2024;149:585-600

[24] Wallentin L,Budaj A.Ticagrelor versus clopidogrel in patients with acute coronary syndromes.N Engl J Med2009;361:1045-57

[25] Wiviott SD,McCabe CH.Prasugrel versus clopidogrel in patients with acute coronary syndromes.N Engl J Med2007;357:2001-15

[26] Bonaca MP,Cohen M.Long-term use of ticagrelor in patients with prior myocardial infarction.N Engl J Med2015;372:1791-800

[27] Sibbing D,Morath T.Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.J Am Coll Cardiol2009;53:849-56

[28] Galli M,Capodanno D.Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.Lancet2021;397:1470-83

[29] Moussa ID,Saucedo J.Trends and outcomes of restenosis after coronary stent implantation in the United States.J Am Coll Cardiol2020;76:1521-31

[30] Park DW,Lee JY.C-reactive protein and the risk of stent thrombosis and cardiovascular events after drug-eluting stent implantation.Circulation2009;120:1987-95

[31] Pelliccia F,Niccoli G.In-stent restenosis after percutaneous coronary intervention: emerging knowledge on biological pathways.Eur Heart J Open2023;3:oead083 PMCID:PMC10558044

[32] Nakazawa G,Nakano M.The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents.J Am Coll Cardiol2011;57:1314-22

[33] Otsuka F,Yahagi K.Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment.Eur Heart J2015;36:2147-59

[34] Adriaenssens T,Godschalk TC.Optical coherence tomography findings in patients with coronary stent thrombosis: a report of the PRESTIGE consortium (prevention of late stent thrombosis by an interdisciplinary global European effort).Circulation2017;136:1007-21 PMCID:PMC5598909

[35] Foin N,Ng J.Stent malapposition and the risk of stent thrombosis: mechanistic insights from an in vitro model.EuroIntervention2017;13:e1096-8

[36] Burzotta F,Aurigemma C.Fractional flow reserve or optical coherence tomography to guide management of angiographically intermediate coronary stenosis: a single-center trial.JACC Cardiovasc Interv2020;13:49-58

[37] Nakatani S,Taniike M.Initial findings of impact of strut width on stent coverage and apposition of sirolimus-eluting stents assessed by optical coherence tomography.Catheter Cardiovasc Interv2013;81:776-81

[38] Foin N,Nakatani S.Incomplete stent apposition causes high shear flow disturbances and delay in neointimal coverage as a function of strut to wall detachment distance: implications for the management of incomplete stent apposition.Circ Cardiovasc Interv2014;7:180-9

[39] Lee JM,Kim J.Ten-year trends in coronary bifurcation percutaneous coronary intervention: prognostic effects of patient and lesion characteristics, devices, and techniques.J Am Heart Assoc2021;10:e021632 PMCID:PMC8649555

[40] Inoue T,Morooka T,Node K.Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis.JACC Cardiovasc Interv2011;4:1057-66 PMCID:PMC3341937

[41] Qiu F,Witzenbichler B.Prevalence and clinical impact of tissue protrusion after stent implantation: an ADAPT-DES intravascular ultrasound substudy.JACC Cardiovasc Interv2016;9:1499-507

[42] Prati F,Burzotta F.Clinical impact of OCT findings during PCI: the CLI-OPCI II study.JACC Cardiovasc Imaging2015;8:1297-305

[43] Ali ZA,Maehara A.Optical coherence tomography-guided versus angiography-guided PCI.N Engl J Med2023;389:1466-76

[44] Holm NR,Neghabat O.OCT or angiography guidance for PCI in complex bifurcation lesions.N Engl J Med2023;389:1477-87

[45] Zhang J,Kan J.Intravascular ultrasound versus angiography-guided drug-eluting stent implantation: the ULTIMATE trial.J Am Coll Cardiol2018;72:3126-37

[46] Akers WS,Oestreich JH,Wethington M.Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist.J Clin Pharmacol2010;50:27-35

[47] Safley DM,Kennedy KF.Impact of glycoprotein IIb/IIIa inhibition in contemporary percutaneous coronary intervention for acute coronary syndromes: insights from the national cardiovascular data registry.JACC Cardiovasc Interv2015;8:1574-82

[48] Steg PG,Hamm CW.Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data.Lancet2013;382:1981-92

[49] Grimfjärd P,Erlinge D,James S.Clinical use of cangrelor: nationwide experience from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).Eur Heart J Cardiovasc Pharmacother2019;5:151-7

[50] Gargiulo G,Avvedimento M.Cangrelor, tirofiban, and chewed or standard prasugrel regimens in patients with ST-segment-elevation myocardial infarction: primary results of the FABOLUS-FASTER trial.Circulation2020;142:441-54

[51] Sharifi-Rad J,Ezzat SM.An updated review on glycoprotein IIb/IIIa inhibitors as antiplatelet agents: basic and clinical perspectives.High Blood Press Cardiovasc Prev2023;30:93-107

[52] Byrne RA,Coughlan JJ.2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC).Eur Heart J2023;44:3720-826

[53] Sethi A,Bahekar A.Glycoprotein IIb/IIIa inhibitors with or without thienopyridine pretreatment improve outcomes after primary percutaneous coronary intervention in high-risk patients with ST elevation myocardial infarction-a meta-regression of randomized controlled trials.Catheter Cardiovasc Interv2013;82:171-81

[54] Bianchini F,Ricchiuto A.Combined ultrasound and angiographic guidance to facilitate transradial access procedures.Catheter Cardiovasc Interv2024;103:443-54

[55] Romagnoli E,Trani C,Giannico F.Rationale for intracoronary administration of abciximab.J Thromb Thrombolysis2007;23:57-63

[56] Hahn J,Geum MJ.Intracoronary versus intravenous glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention in patients with STEMI: a systematic review and meta-analysis.Thromb J2023;21:76 PMCID:PMC10347711

[57] Stone GW,Witzenbichler B.Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial.JAMA2012;307:1817-26

[58] Mantis C,Papadakis E,Patsilinakos S.Glycoprotein IIb/IIIa inhibitors in combination with thrombus aspiration with, or without, stent implantation in patients presenting with S-T elevation myocardial infarction and high thrombus burden.Eur J Cardiovasc Nurs2021;20:zvab060.021

[59] Thiele H,Hambrecht R.Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial.Lancet2012;379:923-31

[60] Prati F,Limbruno U.Randomized evaluation of intralesion versus intracoronary abciximab and aspiration thrombectomy in patients with ST-elevation myocardial infarction: the COCTAIL II trial.Am Heart J2015;170:1116-23

[61] Mascelli MA,Damaraju L,Weisman HF.Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade.Circulation1998;97:1680-8

[62] Hirsh J,Halperin JL.Mechanism of action and pharmacology of unfractionated heparin.Arterioscler Thromb Vasc Biol2001;21:1094-6

[63] Jiang W,Du X,Li W.Safety and efficacy study of prourokinase injection during primary percutaneous coronary intervention in acute ST-segment elevation myocardial infarction.Coron Artery Dis2021;32:25-30 PMCID:PMC7713758

[64] Wang X,Wu H.Safety and efficacy of intracoronary prourokinase administration in patients with high thrombus burden.Coron Artery Dis2020;31:493-9

[65] Bianchini E,Buonpane A.Impact of thrombus aspiration on left ventricular remodeling and function in patients with ST-segment elevation myocardial infarction: a meta-analysis of randomized controlled trials.Int J Cardiol2024;397:131590

[66] Jolly SS,Yusuf S.Outcomes after thrombus aspiration for ST elevation myocardial infarction: 1-year follow-up of the prospective randomised TOTAL trial.Lancet2016;387:127-35 PMCID:PMC5007127

[67] Svilaas T,van der Horst IC.Thrombus aspiration during primary percutaneous coronary intervention.N Engl J Med2008;358:557-67

[68] Jolly SS,Džavík V.Thrombus aspiration in ST-segment-elevation myocardial infarction: an individual patient meta-analysis: thrombectomy trialists collaboration.Circulation2017;135:143-52

[69] Fröbert O,Olivecrona GK.Thrombus aspiration during ST-segment elevation myocardial infarction.N Engl J Med2013;369:1587-97

[70] De Vita M,Trani C.Urgent PCI in patients with stent thrombosis: an observational single-center study comparing thrombus aspiration and standard PCI.J Invasive Cardiol2008;20:161-5

[71] Konstantinou K,Alsanjari O.Clinical effectiveness of thrombus aspiration during percutaneous coronary intervention for stent thrombosis in a contemporary setting.Hellenic J Cardiol2022;66:11-8

[72] Lemesle G,Bonello L.Impact of thrombus aspiration use for the treatment of stent thrombosis on early patient outcomes.J Invasive Cardiol2009;21:210-4

[73] Mahmoud KD,van den Heuvel FM,Zijlstra F.Usefulness of thrombus aspiration for the treatment of coronary stent thrombosis.Am J Cardiol2011;108:1721-7

[74] Waldo SW,Yeo KK.Procedural success and long-term outcomes of aspiration thrombectomy for the treatment of stent thrombosis.Catheter Cardiovasc Interv2013;82:1048-53

[75] Sreenivasan J,Jamil Y.Intravascular imaging-guided versus angiography-guided percutaneous coronary intervention: a systematic review and meta-analysis of randomized trials.J Am Heart Assoc2024;13:e031111 PMCID:PMC10926835

[76] Hill JM,Shlofmitz RA.Intravascular lithotripsy for treatment of severely calcified coronary artery disease.J Am Coll Cardiol2020;76:2635-46

[77] Secco GG,Mattesini A.Very high-pressure dilatation for undilatable coronary lesions: indications and results with a new dedicated balloon.EuroIntervention2016;12:359-65

[78] Burzotta F,Di Giusto F.Long-term outcome of percutaneously managed coronary pseudoaneurysm caused by stent fracture.JACC Cardiovasc Interv2024;17:315-6

[79] Mishell JM,Ports TA,Michaels AD.Determination of adequate coronary stent expansion using StentBoost, a novel fluoroscopic image processing technique.Catheter Cardiovasc Interv2007;69:84-93

[80] Alfonso F,Giacoppo D,Byrne RA.Management of in-stent restenosis.EuroIntervention2022;18:e103-23 PMCID:PMC9904384

[81] Restivo A,Bellamoli M.Intravascular ultrasound-guided 'OrbiTripsy' for a severely calcified neo-atherosclerotic coronary in-stent restenosis.J Cardiovasc Med2023;24:931-2

[82] De Maria GL, Scarsini R, Banning AP. Management of calcific coronary artery lesions: is it time to change our interventional therapeutic approach?.JACC Cardiovasc Interv2019;12:1465-78

[83] Merinopoulos I,Corballis N.Assessment of paclitaxel drug-coated balloon only angioplasty in STEMI.JACC Cardiovasc Interv2023;16:771-9

[84] Abdelaziz A,Atta K.Drug-coated balloons versus drug-eluting stents in patients with acute myocardial infarction undergoing percutaneous coronary intervention: an updated meta-analysis with trial sequential analysis.BMC Cardiovasc Disord2023;23:605 PMCID:PMC10709955

[85] Cortese B,Bathia G.The evolution and revolution of drug coated balloons in coronary angioplasty: an up-to-date review of literature data.Catheter Cardiovasc Interv2023;102:1069-77

[86] Giacoppo D,Xu B.Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study).Eur Heart J2020;41:3715-28

[87] Clare J,Bursill CA,Kingshott P.The mechanisms of restenosis and relevance to next generation stent design.Biomolecules2022;12:430 PMCID:PMC8945897